Squarepoint’s Petros Pharmaceuticals PTPI Stock Holding History

Squarepoint’s Portfolio PTPI Stock Details PTPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-143	Closed	-$119K	–	3381
2021 Q4	$119K	Buy	+143	New	+$83.8K	﹤0.01%	2876

Other funds holding PTPI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Squarepoint's PTPI Position: Q1 2022 in Review

Squarepoint sold out of Petros Pharmaceuticals (PTPI) in Q1 2022, closing a stake of 143 shares — an estimated $119K sold.

Squarepoint first reported a position in PTPI in Q4 2021 and held it in 1 quarter. The position peaked at $119K in Q4 2021. 16 funds tracked by Wall St. Rank hold PTPI as of Q1 2022.

Squarepoint reported no remaining Petros Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Squarepoint sold 143 Petros Pharmaceuticals shares in Q1 2022, an estimated $119K.
Squarepoint first reported a position in Petros Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Squarepoint's Petros Pharmaceuticals position peaked at $119K in Q4 2021.
16 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q1 2022.

Based on Squarepoint's 13F filing for Q1 2022, filed 16 May 2022.